These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. COX-2 inhibitors still eyed for cancer prevention. Thompson CA Am J Health Syst Pharm; 2005 May; 62(9):890, 894. PubMed ID: 15851492 [No Abstract] [Full Text] [Related]
3. Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis. Henderson P JAMA; 2002 Apr; 287(14):1799; author reply 1799-800. PubMed ID: 11939848 [No Abstract] [Full Text] [Related]
4. Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis. Bierma-Zeinstra SM; Bohnen AM; Berger MY; Thomas S JAMA; 2002 Apr; 287(14):1799; author reply 1799-800. PubMed ID: 11939847 [No Abstract] [Full Text] [Related]
10. COX-2-specific inhibition: implications for clinical practice. Pascucci RA J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S18-22. PubMed ID: 10643177 [TBL] [Abstract][Full Text] [Related]
11. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex). Wynn RL Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547 [No Abstract] [Full Text] [Related]
12. [Current status of COX II inhibitors in therapy of rheumatoid arthritis in comparison with conventional non-steroidal anti-inflammatory agents. Attempt at an evaluation with regard to evidence-based medicine]. Krüger K Z Rheumatol; 2001 Dec; 60(6):481-4. PubMed ID: 11826746 [No Abstract] [Full Text] [Related]
14. Decisions loom on selective COX-2 inhibitors. Miller JL Am J Health Syst Pharm; 1999 Jan; 56(2):106-7. PubMed ID: 10030522 [No Abstract] [Full Text] [Related]
15. [Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered]. MMW Fortschr Med; 2003 Mar; 145(10):60. PubMed ID: 12688036 [No Abstract] [Full Text] [Related]
16. [Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives]. Rioda WT; Nervetti A Acta Biomed Ateneo Parmense; 2001; 72(3-4):55-64. PubMed ID: 11889908 [TBL] [Abstract][Full Text] [Related]
17. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Hochberg MC Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246 [TBL] [Abstract][Full Text] [Related]
19. [Cox-2 inhibitors in the focus. Rofecoxib as effective as the "classics"]. MMW Fortschr Med; 2001 Nov; 143(46):50-1. PubMed ID: 11759601 [No Abstract] [Full Text] [Related]
20. Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib. Brinker A; Nourjah P Am J Health Syst Pharm; 2005 Apr; 62(7):739-43. PubMed ID: 15790802 [No Abstract] [Full Text] [Related] [Next] [New Search]